A Phase I/II, Randomized, Double Blind, Placebo-controlled Clinical Study of IMM529 for the Treatment of Clostridium-difficile Infection (CDI).

Trial Profile

A Phase I/II, Randomized, Double Blind, Placebo-controlled Clinical Study of IMM529 for the Treatment of Clostridium-difficile Infection (CDI).

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Jan 2018

At a glance

  • Drugs IMM 529 (Primary)
  • Indications Clostridium-difficile-infections
  • Focus Adverse reactions; First in man
  • Sponsors Immuron
  • Most Recent Events

    • 31 Jan 2018 According to an Immuron media release, topline results are anticipated in the first quarter of 2019.
    • 31 Jan 2018 According to an Immuron media release, the first patient has been enrolled at Hadassah Medical Center in Israel.
    • 19 Nov 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top